home / stock / bmnd:cc / bmnd:cc news

BMND:CC News and Press, BIOMIND LABS INC. From 04/26/22

Stock Information
Company Name: BIOMIND LABS INC.
Stock Symbol: BMND:CC
Market: AQNC
Menu
BMND:CC BMND:CC Quote BMND:CC Short BMND:CC News BMND:CC Articles BMND:CC Message Board
Get BMND:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BMND:CC - Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...
BMND:CC - Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatri...

BMND:CC - Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...

BMND:CC - Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatri...
BMND:CC - Biomind Labs Opens a New Clinical Psychedelic Research Facility

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...

BMND:CC - Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: CRSWF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...

BMND:CC - Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: CRSWF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...
BMND:CC - Biomind Labs Announces DTC Eligibility in the United States

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: CRSWF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...

BMND:CC - Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: CRSWF ) ( FSE: 3XI ), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) fo...

Previous 10 Next 10